The Food and Drug Administration issued a warning letter to Replidyne, Inc. regarding the company's role as applicant of a marketing application in support of an unnamed drug.
The FDA has posted to its a website a warning letter sent to Novartis Vaccines and Diagnostics Gmbh & Co. KG.
No comments:
Post a Comment